Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Highlights in heart failure.
Tomasoni D, Adamo M, Lombardi CM, Metra M. Tomasoni D, et al. Among authors: lombardi cm. ESC Heart Fail. 2019 Dec;6(6):1105-1127. doi: 10.1002/ehf2.12555. ESC Heart Fail. 2019. PMID: 31997538 Free PMC article. Review.
Is there a role for ivabradine beyond its conventional use?
Bonadei I, Vizzardi E, Sciatti E, Carubelli V, Lombardi CM, D'Aloia A, Metra M. Bonadei I, et al. Among authors: lombardi cm. Cardiovasc Ther. 2014 Aug;32(4):189-92. doi: 10.1111/1755-5922.12080. Cardiovasc Ther. 2014. PMID: 24828443 Free article. Review.
Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion?
Adamo M, Chiari E, Curello S, Maiandi C, Chizzola G, Fiorina C, Frontini M, Cuminetti G, Pezzotti E, Rovetta R, Lombardi CM, Manzato A, Metra M, Ettori F. Adamo M, et al. Among authors: lombardi cm. Eur J Heart Fail. 2016 Oct;18(10):1278-1286. doi: 10.1002/ejhf.520. Epub 2016 Apr 22. Eur J Heart Fail. 2016. PMID: 27102848 Free article.
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.
Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, Belotti A, Rossi G, Metra M, Raddino R. Gavazzoni M, et al. Among authors: lombardi cm. Eur J Pharmacol. 2018 Nov 5;838:85-90. doi: 10.1016/j.ejphar.2018.09.014. Epub 2018 Sep 7. Eur J Pharmacol. 2018. PMID: 30201379 Free article.
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators. Kapelios CJ, et al. Eur J Heart Fail. 2019 Nov;21(11):1383-1397. doi: 10.1002/ejhf.1532. Epub 2019 Jun 18. Eur J Heart Fail. 2019. PMID: 31132222 Free article.
201 results